Human biology. Measured with purpose. Advancing medicines with confidence.
Our systems connect human cells to clinical insight—reducing uncertainty and improving the path from discovery to patients.
Science
Building human biology in the lab
Drug development depends on one fundamental question: how will a medicine behave in the human body?
Yet much of preclinical research still relies on models that only approximate human biology- close enough to study, not close enough to trust. myriamed’s approach is to build human-relevant biological systems that allow researchers to observe disease, measure function and study drug responses with a level of biological fidelity that surrogate models cannot offer. The goal is not simply to grow human cells in a dish. It is to recreate the organization, the structure and the functional behaviour that makes human tissue act like human tissue.
By connecting these layers of biology, we can measure function, reveal disease phenotypes and uncover responses that conventional models routinely miss, thus generating deeper insight and enabling better decisions, earlier.
From human biology to meaningful insight
Building human-relevant systems that reveal biology and inform better decisions
HUMAN CELLS
Defined. Human. Relevant.
iPSC-derived human cells with well-defined identity and quality form the foundation.
HUMAN MUSCLE
Organized. Engineered. Functional.
Cells are organized into 3D muscle structures that recapitulate key aspects of human muscle architecture.
MUSCLE FUNCTIONING
Measurable. Quantitative. Predictive.
Muscle function is measured over time to capture physiological behavior and drug responses with precision.
DISEASE
Relevant. Reproducible. Informative.
Disease phenotypes are modeled in human muscle, revealing mechanisms and phenotypic signatures.
DRUG RESPONSE
Responds. Predicts. Guides.
Drug responses are quantified to understand efficacy, potency and mechanism – supporting better decisions earlier.
A scientific foundation built over decades
The science behind myriamed began with a question that was, at the time, far from settled: can functional human tissue be built outside the body and if so, can it help us understand disease and develop better therapies?
For more than two decades, Prof. Wolfram-Hubertus Zimmermann and his team have progressively answered that question. What began with engineered heart tissue evolved through cardiac repair, long-term tissue engraftment, defined human engineered heart muscle, disease modelling, scalable production and, ultimately, clinical translation. Each step addressed a new challenge: how to build tissue, make it functional, reproduce it reliably, measure its behaviour and translate what we learn into therapeutic applications.
The science did not arrive fully formed. It was built – carefully, step by step.
Evolution of Engineered Heart Muscle (EHM) Model
From foundational tissue engineering to clinical translation
1999
3D EHT
established
Neonatal rat EHT established.
Zimmermann et al.,
Biotechnol Bioeng
2006
Functional repair after MI
EHT grafts improve cardiac function.
Zimmermann et al.,
Nat Med
2015
Long-term EHM engraftment
Human EHM in post-MI model.
Reigler et al.,
Circ Res
2017
Defined human EHM
Maturation + disease phenotypes.
Tiburcy et al.,
Circulation
2020
Scalable 48-EHM workflow
Parallel tissue production & screening.
Tiburcy et al.,
STAR Protocols
2025
Clinical
translation
EHM allografts in primates and humans.
Jebran et al.,
Nature
2026
First phase 1/2 clinical report
BioVAT in advanced HF.
Zimmermann et al.,
N Engl J Med.
From proof of concept to functional repair
From animal models to human biology
From research bench to platform
From manual methods to scalable workflows
From laboratory to patients
Science that moves with the field
Science that moves with the field
The scientific landscape around drug development is shifting and the regulatory environment is beginning to catch up. The FDA Modernization Act 2.0 opened the door for non-animal approaches in drug development. The FDA's 2025 Roadmap for Reducing Animal Testing established a stepwise strategy for integrating scientifically validated New Approach Methodologies. In 2026, draft guidance provided a framework for their validation and regulatory use. Taken together, these steps mark a meaningful turning point.
For myriamed, this is more than a regulatory shift. It is a recognition of the scientific direction we have pursued for decades that human-relevant biology deserves a central place in the decisions that shape drug development. We were not building our platform to respond to this moment. We built it because we believed this moment would come.
Our science. One continuum.
Building human-relevant systems that reveal biology and drive better decisions.
From cells
to tissues
From tissues
to function
from function
to insight
From insight
to better medicines
Human biology at every step of drug discovery.
Better data. Better decisions. Better medicines.
